Alfred King-yin Lam
Bin Li
Linhui Liang
Jianjun Xie
Wen Wen Xu- 1School of Medicine & Dentistry and Menzies Health Institute Queensland, Griffith University, Gold Coast, QSL, Australia
- 2The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
- 3Fudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, China
- 4Department of Biochemistry and Molecular Biology, Shantou University Medical College, Shantou, China
- 5Guangzhou Medical University, Guangzhou, China
Editorial on the Research Topic
Novel Molecular Targets and Treatments for Gastroesophageal Cancer
In this Research Topic, we collected 20 papers under the title of “Novel Molecular Targets and Treatments for gastroesophageal Cancer” (Das et al., Power et al., Heng et al., Islam et al., Wang et al., Li et al., Zhang et al., Zhang et al., Deng et al., Bai et al., Lv et al., Guo et al., Chen et al., Luan et al., Jiang et al., Jafarzadeh and Soltani, Jin et al., Fang et al., Wang et al., Chen et al.). Cancers of the oesophagus and stomach account for 8.7% of new cases and 13.2% of new deaths of all sites worldwide (1). In the World Health Organization (WHO) classification of tumours, oesophageal cancer has two major histological types, namely squamous cell carcinoma (SCC) and adenocarcinoma (2). SCC is mostly noted in the upper and middle oesophagus and occurs mainly in high incidence regions such as in China, whereas adenocarcinoma is mostly in the lower oesophagus and oesophagogastric junction and is mostly in low incidence regions of high income and excess body weight. Recently, datasets reporting carcinoma of the oesophagus have been developed by the International Collaboration on Cancer Reporting (ICCR) (3, 4) to standardize the pathological reporting of cancer which allow a better base for research and improvement of management.
Among the papers focused on oesophageal cancer in this Research Topic, Das et al. review the therapeutic strategies against cancer stem cells, whereas Power et al. analyse immunotherapy approaches for oesophageal carcinomas. These papers open new avenues for innovative treatment of this cancer. The other papers are original studies based on SCCs from China, a high incidence area. Of these, Heng et al. studied the mechanisms and roles of camptothecin (anticancer agent) in oesophageal SCC cells. Islam et al. characterized the clinicopathological roles of molecular deregulation of Endothelial PAS domain-containing protein 1 (EPAS1) (code for an angiogenic factor) in 80 Hong Kong patients with oesophageal SCCs. In addition, the expression profiles of microRNAs could be useful as prognostic, and predictive biomarkers in oesophageal carcinomas (5). Wang et al. highlight the potential molecular target roles of miR-17-5p and miR-443 in the treatment of oesophageal SCC.
Spindle cell SCC is an uncommon subtype of SCC (2, 6). Li et al. analysed one of the largest series (n=43) of this cancer subtype in Southern China and developed a risk stratification and personalized management model. In the same centre, Zhang et al. analysed the ABO blood type in blood samples from 2179 patients with oesophageal carcinomas revealing that blood types had independent prognostic roles. Lastly, Zhang et al. from Shanghai reported the tumour-suppressive effect of Chinese herbal monomer, fangchinoline on oesophageal SCC cells.
Gastric cancer, predominately adenocarcinoma, is more common than oesophageal cancer, ranking fifth for incidence and fourth for mortality globally (1). Dataset reporting of carcinoma of the stomach has also been developed by ICCR (7) to standardize the pathological reporting of gastric carcinoma. In this area, Deng et al. reviewed the potential clinical value of tetraspanins in the management of gastric carcinoma. In addition, Bai et al. reviewed the advances and markers of immunotherapy in the treatment of patients with gastric adenocarcinoma and oesophagogastric adenocarcinoma. Lv et al. from China studied the expression of programmed death-ligand 1(PDL-1; predictor for immunotherapy), HER-2 (human epidermal growth factor receptor 2; predictor for anti-HER 2-antibody therapy), immune microenvironment, and clinical features in 120 gastric adenocarcinomas. They noted that HER-2 status could predict the efficacy of immune checkpoint inhibitors and HER-2 status combined with PD-L1 level could predict the prognosis of patients tithe gastric carcinomas.
At the DNA level, Guo et al. analysed blood samples from 640 gastric adenocarcinomas from Chinese patients as well as gastric carcinoma cell lines and showed that tumour necrosis factor alpha-induced protein 2 (TNFAIP2) polymorphism (rs8126 TC genotype) had a high risk of gastric carcinoma in male, elderly patients who are Helicobacter pylori-negative, non-smoking, and non-drinking individuals.
Gene expressions were studied in gastric carcinomas to investigate mechanistic pathways as well as their potential for target therapies. Chen et al. reported the expression of the transcription factor regulation gene, PLXNC1 (transcriptional factor plexin C1) in 111 gastric adenocarcinomas from Chinese patients and gastric carcinoma cell lines. The results showed that PLXNC1 plays an oncogenic role in gastric adenocarcinoma and could act as a therapeutic target. Luan et al. studied the expression of the TOR signalling pathway regulator (TIPRL) in 230 gastric carcinomas from Chinese patients, revealing that it suppresses cell migration and invasion by regulating the AMPK/mTOR signalling pathway in cancer. In addition, in 74 Chinese patients with gastric carcinoma and cancer cells, Jiang et al. showed that expression of fibronectin type III domain containing 1 (FNDC1) promotes the invasiveness of gastric cancer via the Wnt/β-catenin signalling pathway and correlates with peritoneal metastasis and prognosis.
Non-coding RNAs may include microRNAs, long noncoding RNAs (IncRNAs), and circular RNAs (cirRNAs) (8). Jafarzadeh and Soltanil from Iran demonstrated that InCRNA LOC400043 inhibits gastric cancer progression by regulating the Wnt signalling pathway in 15 gastric carcinomas and cell lines. In addition, Jin et al. demonstrated in 31 cases of gastric carcinomas from China and cancer cell lines that cirRNA promotes metastases under a long-term hypoxic microenvironment.
Proteins in carcinoma could alter tumour microenvironments such as matrix and cancer cell adhesions. In this aspect, Fang et al. studied the junctional adhesion molecular-like protein in 63 gastric carcinomas from Chinese patients and noted that it promotes tumour progression and metastases via the p38 signalling pathway. Wang et al. showed that a high level of legumain, with critical roles in extracellular matrix degradation and modelling, was associated with worse prognosis and peritoneal metastases in 139 Chinese patients with gastric carcinoma. Furthermore, Chen et al. studied the expression of myeloid differentiation factor 88 (MyD88), an adaptor molecule in Toll-like signalling pathway recognizing Helicobacter pylori, in 102 proximal gastric adenocarcinomas from Chinese patients by immunohistochemistry. MyD88 expression correlates with tumour grade and NF-kB p105/p50 expression.
To conclude, the papers in this Research Topic summarize current and novel molecular targets and treatments for oesophageal cancer and gastric cancer. This will enrich our understanding of pathogenesis and treatment possibilities, leading to the potential improvement of clinical outcomes of cancer.
Author Contributions
AL conceptualized, designed, and wrote the editorial. All the authors contributed and approved the submitted version.
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin (2021) 71:209–49. doi: 10.3322/caac.21660
2. Lam AK. Updates on World Health Organization Classification and Staging of Esophageal Tumors: Implications for Future Clinical Practice. Hum Pathol (2021) 108:100–12. doi: 10.1016/j.humpath.2020.10.015
3. Lam AK, Nagtegaal ID. Committee for the Development of the ICCR Dataset for Endoscopic Resection of the Esophagus and Esophagogastric Junction. Pathology Reporting of Esophagus Endoscopic Resections: Recommendations From the International Collaboration on Cancer Reporting. Gastroenterology (2022) 162:373–8. doi: 10.1053/j.gastro.2021.09.069
4. Lam AK, Bourke MJ, Chen R, Fiocca R, Fujishima F, Fujii S, et al. Dataset for the Reporting of Carcinoma of the Esophagus in Resection Specimens: Recommendations From the International Collaboration on Cancer Reporting. Hum Pathol (2021) 114:54–65. doi: 10.1016/j.humpath.2021.05.003
5. Islam F, Gopalan V, Lam AK. Roles of microRNAs in Esophageal Squamous Cell Carcinoma Pathogenesis. Methods Mol Biol (2020) 2129:241–57. doi: 10.1007/978-1-0716-0377-2_18
6. Lam KY, Law SY, Loke SL, Fok M, Ma LT. Double Sarcomatoid Carcinomas of the Oesophagus. Pathol Res Pract (1996) 192:604–9. doi: 10.1016/S0344-0338(96)80112-9
7. Shi C, Badgwell BD, Grabsch HI, Gibson MK, Hong SM, Kumarasinghe P, et al. Data Set for Reporting Carcinoma of the Stomach in Gastrectomy. Arch Pathol Lab Med (2022). doi: 10.5858/arpa.2021-0225-OA
Keywords: esophagus, stomach, gastroesophageal, adenocarcinoma, squamous cell carcinoma, genomics, target therapy, molecular markers
Citation: Lam AK-y, Li B, Liang L, Xie J and Xu WW (2022) Editorial: Novel Molecular Targets and Treatments for Gastroesophageal Cancer. Front. Oncol. 12:888861. doi: 10.3389/fonc.2022.888861
Received: 03 March 2022; Accepted: 29 March 2022;
Published: 13 May 2022.
Edited and reviewed by:
Liang Qiao, Westmead Institute for Medical Research, AustraliaCopyright © 2022 Lam, Li, Liang, Xie and Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Alfred King-yin Lam, YS5sYW1AZ3JpZmZpdGguZWR1LmF1; Bin Li, bGliaW4yMDE1QGpudS5lZHUuY24=